Barbara   Burtness , MD

Barbara Burtness , MD

Yale Cancer Center/Smilow Cancer Hospital

Professor of Medicine (Medical Oncology); Chief Translational Research Officer, Yale Cancer Center; Chief, Head and Neck Cancers/Sarcoma; Co-Leader, Developmental Therapeutics, Yale Cancer Center

Expertise: Head And Neck CancerHead And Neck CancerMedical OncologyMedical OncologySarcomaSarcoma

Barbara Burtness, MD is a Professor of Medicine (Medical Oncology) at the Yale School of Medicine, Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research at the Yale Cancer Center. She serves as Co-Leader of the Developmental Therapeutics Program, Division Chief for Head and Neck/Sarcoma Oncology, and Director of the Yale Head and Neck Specialized Program of Research Excellence. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advanc, and leads national and international trials of targeted therapy in head and neck cancer. Her laboratory studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and - in lung cancer- to direct KRAS inhibition. 

No Clipping

No Research/Citations

Reducing Radiation After Surgery Prolongs Survival for Some Patients With HPV-Related Throat Cancer

Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study.
29-May-2024 11:05:48 AM EDT

New Research and Treatment Advances From Yale Cancer Center to be Presented at the World’s Largest Cancer Research Conference

Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.
13-May-2024 11:05:20 AM EDT

Researchers develop a new way to classify HPV-associated head and neck cancers

Human papillomavirus (HPV) has been linked to a significant increase in cancers of the throat and tonsils over the past few decades; this is projected to become the most common form of head and neck cancer by 2030. But a major limitation to reducing treatment intensity is the inability to correctly identify the patients whose HPV-related cancers will be the most responsive to treatment.
31-Jul-2023 03:05:36 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.08191